Glancy Prongay & Murray LLP, a leading securities fraud law firm, announces an investigation of Ampio Pharmaceuticals, Inc. (AMPE) on behalf of investors

LOS ANGELES–(BUSINESS WIRE)–Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has initiated an investigation on behalf of Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (US NYSE: AMPE) regarding the Company’s possible violations of federal securities laws.

If you have suffered a loss on your Ampio investments or would like to inquire about possible claims to recover your loss under federal securities laws, you may submit your contact information at cases/ampio-pharmaceuticals-inc-1/. You may also contact Charles H. Linehan of GPM at 310-201-9150, toll-free at 888-773-9224, or by email at [email protected] to learn more about your rights.

On April 20, 2022, Ampio announced that the United States Food and Drug Administration (“FDA”) had responded negatively to its Type C meeting request for the Company’s AP-013 clinical trial and that the FDA had concluded that the Company should have requested the FDA’s approval of changes made to the data analysis before analyzing and unblinding the data. On this news, the Company’s stock price fell $0.09, or 26%, to close at $0.25 per share on April 21, 2022.

Then, on May 16, 2022, Ampio announced that it had formed a special committee to conduct an internal investigation focused on Ampio’s AP-013 clinical trial and the unauthorized supply of its anti-inflammatory drug Ampion to the use by persons not participating in clinical trials. On this news, the Company’s stock price fell $0.04, or 10%, to close at $0.18 per share on May 18, 2022.

Then, on August 3, 2022, Ampio revealed that, as of March 2020, “senior executives were aware. . . that the AP-013 trial did not demonstrate the efficacy of Ampion on its co-primary endpoints of pain and function; and that these individuals have not fully reported the results of the AP-013 trial and the timing of the unblinding of the AP-013 trial data.” The Company also disclosed “that certain members of the Ampio personnel, including a former officer and certain former directors, facilitated the provision of Ampion for unauthorized use.”

On this news, Ampio’s stock fell $0.06, or 37.5%, to close at $0.10 per share on August 3, 2022, hurting investors.

Follow us for updates on LinkedIn, Twitteror facebook.

Notice of denunciation: People with nonpublic information about Ampio should consider their options to help the investigation or take advantage of the SEC’s whistleblower program. Under this program, whistleblowers who provide original information can receive rewards of up to 30% of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email [email protected]

About GPM

Glancy Prongay & Murray LLP is a leading law firm representing investors and consumers in securities litigation and other complex class actions. ISS Securities Class Action Services has consistently ranked GPM in its annual SCAS Top 50 report. In 2018, GPM was ranked among the top five law firms for the number of securities class action settlements and among the top six law firms for the full amount of the settlements. With four offices across the country, nearly 40 GPM attorneys have won groundbreaking decisions and recovered billions of dollars for investors and consumers in securities, antitrust, consumer and employment class action lawsuits. GPM attorneys have handled cases covering a wide range of corporate misconduct, including cases involving financial restatements, internal control weaknesses, earnings management, fraudulent earnings advice and forward-looking statements, audit misconduct, insider trading, violations of FDA regulations, actions resulting in FDA and DOJ investigations, and many other forms of corporate misconduct. GPM’s attorneys have worked on securities matters involving nearly every industry and sector of the capital markets, including energy, consumer discretionary, consumer staples, real estate and REITs, financials, insurance, information technology, healthcare, biotechnology, cryptocurrency, medical devices. , and much more. GPM’s past successes have been widely covered by major industry news and publications such as The Wall Street Journal, The Financial Times, Bloomberg Business Week, Reutersthe Associated press, Barrons, Investor Business Daily, Forbesand Silver.

This press release may be considered attorney advertising in certain jurisdictions under applicable law and ethics rules.